Overview

Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery

Status:
Completed

Trial end date:
2018-05-06

Target enrollment:

Participant gender:

Summary

This phase I trial studies the side effects and best dose of ipilimumab when given together with gemcitabine hydrochloride in treating patients with stage III-IV or recurrent pancreatic cancer that cannot be removed by surgery. Monoclonal antibodies, such as ipilimumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or tumor-killing substances to them. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to kill tumor cells or stop them from growing. Giving monoclonal antibody therapy together with chemotherapy may kill more tumor cells.

Phase:

Phase 1

Details

Lead Sponsor:

Northwestern University

Collaborator:

Robert H. Lurie Cancer Center

Treatments:

Antibodies
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Gemcitabine
Immunoglobulins
Ipilimumab